genprowebdirectory
GEN Edge
News
Insights
Trends for 2020
A-Lists
Topics
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Magazine
Supplement
Resources
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Advertising
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Webinar Sponsorship
eBook Advertising
Email Nurture Campaigns
Ad Terms and Conditions
About GEN
Contact GEN
Create a Free Account
Get GEN Edge
Log In
GEN – Genetic Engineering and Biotechnology News
Mary Ann Liebert, Inc. Publishers
GEN Edge
Coronavirus
COVID-19 Puts Spotlight on Artificial Intelligence
Data Management
VAST Ambition When It Comes To Data Storage
Antisense
NeuBase Sets a Course for the Clinic
Bioprocessing
Cytiva Picks Up Where GE Leaves Off after $21B Deal
Coronavirus
Putting COVID-19 on the ‘Map’
News
Cardiovascular Testing
Over 200 Genetic Factors Found Linked to Heart Arrhythmias
Bioprocessing
Cytiva Teams Up with Takara Bio to Work on COVID-19 Vaccine…
Bioprocessing
Rentschler Biopharma Licenses Horizon Discovery’s CHOSOURCE Platform
OMICs
Ketogenic Diet Alters Gut Microbiome Leading to Reduced Levels of Proinflammatory…
Coronavirus
SARS-CoV-2 Prototype Vaccine Protects Macaques
Insights
All
Trends for 2020
Bioprocessing
Introducing New Bioprocessing Technologies in the Era of COVID-19
Bioprocessing
Smart AI Use Could Benefit Biopharma
Bioprocessing
Digital Ecosystem Combines Process Control, Analytics, and Plant-Level Automation
Bioprocessing
Coronavirus Vaccine Race Approaching Quality Control Hurdle
A-Lists
Coronavirus
Blinking Red: 25 Missed Pandemic Warning Signs
Coronavirus
Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development
Coronavirus
Catching Up to Coronavirus: Top 60 Treatments in Development
Drug Discovery
Top 15 Best-Selling Drugs of 2019
Coronavirus
How to Conquer Coronavirus: Top 35 Treatments in Development
Topics
All
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Sponsored
Saving Science by Saving Mice
Bioprocessing
Cytiva Teams Up with Takara Bio to Work on COVID-19 Vaccine…
Bioprocessing
Rentschler Biopharma Licenses Horizon Discovery’s CHOSOURCE Platform
Upcoming Webinars
Looking toward the Future of Cell & Gene Therapies
Magazine
All
Supplement
Coronavirus
Race for a Coronavirus Vaccine
Drug Discovery
Protein Modulation Helps Drug Design Get a Grip
OMICs
Proteomic Mass Spec Assesses Biomolecular Teamwork
Coronavirus
COVID-19 Drives CRISPR Diagnostics
Resources
All
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Upcoming Webinars
Looking toward the Future of Cell & Gene Therapies
Upcoming Webinars
DNA as Medicine: Encoding Cancer Therapeutic Antibodies
GENcast
Trends in Bioprocess 4.0 and their Impact on Biomanufacturing
Upcoming Webinars
Streamlining High-Throughput Impurity Analysis in Process Development
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Home
Blood Disorders
Blood Disorders
Random
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Blood Disorders
Affymax Achieves $50M Milestone in Anemia Deal with Takeda
Blood Disorders
Spark Therapeutics Stock Tumbles after Mixed Results from Phase I/II Trial of Hemophilia A Candidate
Blood Disorders
Argenx Halts Collaboration to Develop ARGX-110 for Rare Blood Cancer
Blood Disorders
GSK Reports Japanese Clearance for ITP Drug as Partner Ligand Gets $2M in Govt Grants
Blood Disorders
Triple Threat: Gene Controls Three Diseases
Blood Disorders
Gene Therapy for Sickle Cell Aces Vital Preclinical Test
Blood Disorders
Sangamo CEO Looks Long-Term toward In Vivo Genome Editing, Regulation
Blood Disorders
Sandoz’ Biosimilar to Amgen’s Anemia Drug Gets EU Go-Ahead
Blood Disorders
Takeda Sells Two Drugs for $5.7B+, Licenses a Third, in Deals...
Blood Disorders
Senescent Cells Promote Blood Clotting
Blood Disorders
Mathematical Model Predicts Infection Risk in Chemotherapy Patients
Blood Disorders
Roche Buys CMI, Creates Hematology Dx Hub In $220M+ Deal
Blood Disorders
Takeda Backs Out of Commercializing Affymax’ Anemia Drug in Japan
Blood Disorders
Chiesi Ends Collaboration with uniQure on Hemophilia B Gene Therapy Candidate
Blood Disorders
Pfizer Negotiates Global Rights to GlycoMimetics’ Phase II Sickle Cell Crisis...
1
2
3
...
14
Page 1 of 14
Scroll Up
Please wait while you are redirected to the right page...
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
/* The alert message box */ .alert { padding: 20px; background-color: #ff9800; /* Red */ color: white; margin-bottom: 15px; } /* The close button */ .closebtn { margin-left: 15px; color: white; font-weight: bold; float: right; font-size: 22px; line-height: 20px; cursor: pointer; transition: 0.3s; } /* When moving the mouse over the close button */ .closebtn:hover { color: black; } .td_module_flex_2 .entry-title { font-size: 17px; line-height: 20px; }
![New research suggest ketogenic diets may cause an increased risk of Type 2 diabetes in the early stage of the diet. [United States Air Force]](https://www.genengnews.com/wp-content/uploads/2018/08/Aug9_2018_KirtlandAirForceBase_KetogenicDiet_SalmonButterOliveOilCoconutSteak1801911782-218x150.jpg "Ketogenic Diet Alters Gut Microbiome Leading to Reduced Levels of Proinflammatory T Cells")
![Spark Therapeutics saw its share price tumble about 30% in early-morning trading after it reported mixed preliminary data this morning from a Phase I/II trial of its hemophilia A gene therapy candidate SPK-8001. [Source: wildpixel/Getty Images]](https://www.genengnews.com/wp-content/uploads/2018/08/Dec7_2017_Getty_487489316_GeneTherapy_60019871441892139879144-265x198.jpg "Spark Therapeutics Stock Tumbles after Mixed Results from Phase I/II Trial of Hemophilia A Candidate")
